Found: 35
Select item for more details and to access through your institution.
Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2005, v. 21, n. 4, p. 313, doi. 10.1002/dmrr.553
- By:
- Publication type:
- Article
GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2003, v. 19, n. 2, p. 115, doi. 10.1002/dmrr.357
- By:
- Publication type:
- Article
The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects.
- Published in:
- European Journal of Endocrinology, 2002, v. 146, n. 6, p. 863, doi. 10.1530/eje.0.1460863
- By:
- Publication type:
- Article
Pancreas duodenum homeobox-1 regulates pancreas development during embryogenesis and islet cell function in adulthood.
- Published in:
- European Journal of Endocrinology, 2002, v. 146, n. 2, p. 129, doi. 10.1530/eje.0.1460129
- By:
- Publication type:
- Article
Glucagon-like peptide-1: a major regulator of pancreatic &bgr;-cell function.
- Published in:
- European Journal of Endocrinology, 2000, v. 143, n. 6, p. 717
- By:
- Publication type:
- Article
Insulin, but Not Insulin-like Growth Factor-I, Is Expressed during Early Nervous System Development in Prepancreatic Xenopus Embryos.
- Published in:
- Annals of the New York Academy of Sciences, 1993, v. 692, n. 1, p. 268, doi. 10.1111/j.1749-6632.1993.tb26230.x
- By:
- Publication type:
- Article
Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial.
- Published in:
- Cardiovascular Diabetology, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12933-024-02135-z
- By:
- Publication type:
- Article
Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01811-w
- By:
- Publication type:
- Article
The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real‐world setting.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1429, doi. 10.1111/dom.13673
- By:
- Publication type:
- Article
Propensity‐score‐matched comparative analyses of simultaneously administered fixed‐ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 12, p. 2821, doi. 10.1111/dom.13462
- By:
- Publication type:
- Article
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
- Published in:
- Cardiovascular Diabetology, 2017, v. 16, p. 1, doi. 10.1186/s12933-016-0490-6
- By:
- Publication type:
- Article
Qualitative interviews with adults with Classic Galactosemia and their caregivers: disease burden and challenges with daily living.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Understanding the patient experience of Classic Galactosemia in pediatric and adult patients: increased disease burden, challenges with daily living, and how they evolve over time.
- Published in:
- Journal of Patient-Reported Outcomes, 2023, v. 7, n. 1, p. 1, doi. 10.1186/s41687-023-00635-2
- By:
- Publication type:
- Article
Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Activity After Oral Administration of AMG 221, a Selective 11β-HSD1 Inhibitor.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Activity After Oral Administration of AMG 221, a Selective 11β-HSD1 Inhibitor.
- Published in:
- Journal of Clinical Pharmacology, 2011, v. 51, n. 6, p. 830, doi. 10.1177/0091270010374470
- By:
- Publication type:
- Article
Long Acting GLP-1 for the Treatment of Type I Diabetes.
- Published in:
- Diabetes, 2007, v. 56, p. A73
- By:
- Publication type:
- Article
Fatty acid translocase (FAT/CD36) is localized on insulin-containing granules in human pancreatic beta-cells and mediates fatty acid effects on insulin secretion.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Adenovirus-mediated XIAP gene transfer reverses the negative effects of immunosuppressive drugs on insulin secretion and cell viability of isolated human islets.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Glucagon-Like Peptide 1 Induces Differentiation of Islet Duodenal Homeobox-1--Positive...
- Published in:
- Diabetes, 2001, v. 50, n. 4, p. 785, doi. 10.2337/diabetes.50.4.785
- By:
- Publication type:
- Article
3,5,3'-Triiodo-L-thyronine enhances the differentiation of a human pancreatic duct cell line (hPANC-1) towards a -cell-Like phenotypeSilvia Misiti and Emanuela Anastasi contributed equally to this work.
- Published in:
- Journal of Cellular Physiology, 2005, v. 204, n. 1, p. 286, doi. 10.1002/jcp.20293
- By:
- Publication type:
- Article
SWEET - where are we heading with international type 1 diabetes registries?
- Published in:
- Pediatric Diabetes, 2012, v. 13, p. 1, doi. 10.1111/j.1399-5448.2012.00906.x
- By:
- Publication type:
- Article
Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 6, p. 1293, doi. 10.1007/s13300-020-00808-y
- By:
- Publication type:
- Article
Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT‐007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study.
- Published in:
- Journal of Clinical Pharmacology, 2024, v. 64, n. 11, p. 1397, doi. 10.1002/jcph.2495
- By:
- Publication type:
- Article
Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Inheritance of the Arg64 Polymorphic Variants of the ß<sub>3</sub>-Adrenergic Receptor is Linked to Impaired Insulin Secretion.
- Published in:
- International Journal on Disability & Human Development (De Gruyter), 2002, v. 3, n. 2, p. 63
- By:
- Publication type:
- Article
Rational drug design and PPAR Agonists.
- Published in:
- Current Diabetes Reports, 2005, v. 5, n. 5, p. 340, doi. 10.1007/s11892-005-0091-3
- By:
- Publication type:
- Article
379-P: Aldose Reductase Inhibition by AT-001 Prevents Diabetic Cardiomyopathy via Reducing Myocardial Fatty Acid Oxidation Rates.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-379-P
- By:
- Publication type:
- Article
1043-P: Diabetic Cardiomyopathy: A Systematic Analysis of Epidemiological Studies.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-1043-P
- By:
- Publication type:
- Article
462-P: AT-001, a Next Generation Aldose Reductase Inhibitor with Improved Selectivity and Specificity, Protects from Cellular Damage Associated with Hyperglycemia.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-462-P
- By:
- Publication type:
- Article
186-OR: Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM).
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-186-OR
- By:
- Publication type:
- Article
1080-P: Addressing the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy, a Potent and Selective Next Generation Aldose Reductase Inhibitor.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1080-P
- By:
- Publication type:
- Article
145-LB: Phase 1/2 Safety and Proof of Biological Activity Study of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-145-LB
- By:
- Publication type:
- Article